Immunome, Inc. announced the promotion of Max Rosett to Chief Financial Officer, effective May 9. Mr. Rosett most recently held the role of Executive Vice President, Operations, in addition to serving as Immunome?s Interim Chief Financial Officer since January 2024. Max previously served in roles of increasing responsibility at Morphimmune, concluding as Acting Chief Operating Officer, and joinedImmunome in October 2023 at the close of Morphimmune?s merger with Immunome. Prior to Morphimmune, Mr. Rosett was a Principal at Research Bridge Partners, a life science investmentfirm.

He has also worked as a software engineer at Google, and he started his career at the Boston Consulting Group, where he served clients in the pharmaceutical industry. Mr. Rosett earned a M.S. in Computer Science from Georgia Institute of Technology and a B.A. in Mathematics from Yale University.